Liver cancer trial tests combo therapy against single drug
NCT ID NCT07408804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a targeted chemotherapy procedure (TACE) to the drug lenvatinib works better than lenvatinib alone for people with liver cancer that cannot be removed by surgery. About 40 adults with early to advanced liver cancer will be enrolled. The goal is to see if the combination shrinks tumors more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Hepatology, Bangladesh Medical University
RECRUITINGDhaka, 1000, Bangladesh
More trials for these conditions
Other studies related to the condition(s) this trial covers.